| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 9.440 | 83 | 1.154 | 11.193 | 16.285 | 4.282 | 7.454 | 18.538 | 12.364 | 16.176 |
| Total Income - EUR | 9.440 | 83 | 1.154 | 11.200 | 16.285 | 4.282 | 7.780 | 19.536 | 12.364 | 16.176 |
| Total Expenses - EUR | 5.564 | 892 | 2.267 | 11.520 | 19.568 | 1.700 | 6.723 | 6.814 | 984 | 1.100 |
| Gross Profit/Loss - EUR | 3.876 | -809 | -1.113 | -320 | -3.283 | 2.582 | 1.057 | 12.722 | 11.380 | 15.075 |
| Net Profit/Loss - EUR | 3.511 | -811 | -1.148 | -477 | -3.560 | 2.467 | 824 | 12.150 | 9.832 | 13.025 |
| Employees | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 |
Check the financial reports for the company - Poppins Pharma Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 846 | 634 | 424 | 301 | 205 | 147 | 0 | 0 | 0 | 0 |
| Current Assets | 920 | 116 | 402 | 1.527 | 3.365 | 4.714 | 5.325 | 14.361 | 24.486 | 37.569 |
| Inventories | 0 | 0 | 0 | 0 | 860 | 1.273 | 0 | 0 | 110 | 0 |
| Receivables | 312 | 114 | 176 | 739 | 2.106 | 2.453 | 1.806 | 1.135 | 14.652 | 33.892 |
| Cash | 607 | 2 | 226 | 788 | 399 | 988 | 3.519 | 13.226 | 9.724 | 3.677 |
| Shareholders Funds | 45 | -766 | -1.902 | -2.344 | -5.858 | -3.280 | -2.384 | 9.758 | 19.560 | 32.477 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 1.721 | 1.517 | 2.728 | 4.172 | 9.429 | 8.141 | 7.709 | 4.603 | 4.926 | 4.816 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 276 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "7022 - 7022" | |||||||||
| CAEN Financial Year |
7022
|
|||||||||
Comments - Poppins Pharma Srl